设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2018 年第 5 期 第 13 卷

阿托伐他汀钙与低剂量雌激素联合治疗围绝经期女性骨质疏松的临床效果

Clinical effect of atorvastatin calcium combined with low dose estrogen on osteoporosis in peri-menopausal women

作者:姜爱凤王以新马立萍冯妍张佩雪张淼淼    

英文作者:

单位:100029首都医科大学附属北京安贞医院全科医疗科北京市心肺血管疾病研究所

英文单位:

关键词:骨质疏松;围绝经期;阿托伐他汀钙;雌激素

英文关键词:

  • 摘要:
  • 目的    分析阿托伐他汀钙与低剂量雌激素联合治疗围绝经期女性骨质疏松的临床效果。方法    选择2013年1月至2016年1月首都医科大学附属北京安贞医院门诊收治的围绝经期女性骨质疏松患者200例。按照随机数字表法分为对照组和观察组,各100例。对照组予以雌激素治疗,观察组予以阿托伐他汀钙与雌激素联合治疗。比较治疗前后2组患者雌激素、降钙素、骨钙素、骨密度水平。结果    治疗前2组患者的雌激素、降钙素、骨钙素、骨密度水平差异无统计学意义(P>0.05)。治疗后,对照组及观察组雌激素、降钙素、骨钙素、骨密度水平均较治疗前升高,且观察组雌激素、降钙素、骨钙素、骨密度水平明显高于对照组[(32±5)ng/L比(30±5)ng/L、(262±72)ng/L比(232±63)ng/L、(11.5±2.7)μg/L比(9.1±2.2)μg/L、(0.55±0.02)g/cm2比(0.49±0.02)g/cm2],差异均有统计学意义(均P<0.05)。结论    在围绝经期女性骨质疏松治疗中予以阿托伐他汀钙与雌激素联合治疗效果较为理想,对患者骨密度增加具有促进作用。

  • 【Abstract】Objective    To analyze the clinical effect of atorvastatin calcium combined with low dose estrogen on osteoporosis in peri-menopausal women. Methods    Totally 200 cases of postmenopausal women with osteoporosis admitted from January 2013 to January 2016 in Beijing Anzhen Hospital, Capital Medical University were randomly divided into control group and observation group, with 100 cases in each group. The control group was treated with estrogen; the observation group was treated with atorvastatin calcium and estrogen. Changes of estrogen, calcitonin, osteocalcin and bone mineral density were analyzed before and after treatment. Results    There were no significant differences of levels of estrogen, calcitonin, osteocalcin and bone mineral density between groups before treatment(P>0.05). After treatment, levels of estrogen, calcitonin, osteocalcin and bone mineral density significantly increased compared to those before treatment in both groups; levels of estrogen, calcitonin, osteocalcin and bone mineral density in observation group were significantly higher than those in control group[(32±5)ng/L vs (30±5)ng/L, (262±72)ng/L vs (232±63)ng/L, (11.5±2.7)μg/L vs (9.1±2.2)μg/L, (0.55±0.02)g/cm2 vs (0.49±0.02)g/cm2](P<0.05). Conclusion    Atorvastatin calcium combined with estrogen treating postmenopausal women with osteoporosis can effectively increase bone mineral density.

    【Key words】Osteoporosis;Peri-menopausal period;Atorvastatin calcium;Estrogen

    【Fund program】Capital Health Development Research Project of Beijing Municipal Commission of Health and Family Planning(2014-2-1053)


copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭